Foresee Pharmaceuticals Co Ltd(6576)

Description: Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is based in Taipei, Taiwan.

---

Keywords: Medicine Pharmaceutical Organ Systems Prostate Cancer Disorders Asthma Respiratory Diseases Chronic Obstructive Pulmonary Disease Treatment Of Breast Cancer Idiopathic Pulmonary Fibrosis Covid 19 Pulmonary Fibrosis Pulmonology Acute Respiratory Distress Syndrome Central Nervous System Disease Neurological Diseases Sarcoidosis Fanconi Anemia Treatment Of Neurological Diseases

---

Home Page: www.foreseepharma.com

No. 19-3, Sanchong Road
Taipei, 115
Taiwan
Phone: 886 2 7750 0188

---

Officers

Exchange: TWO

Country: TW

Currency: New Taiwan Dollar (NT$)